Stock AnalizRevvity, Inc. RVTY
Biotechnology: Laboratory Analytical Instruments · data as of November 13, 2026
Revvity, Inc. (RVTY) is a industrial company listed in the US with a market value of about $17.2B. In the twelve months to October 4, 2026 it had revenue of $2.9B and net income of $253M, a net margin of 8.6%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is shareholder returns (4/5); the weakest is value (0/5).
Key numbers: a P/E of 68.6, a price to free cash flow of 29.2, 5-year revenue growth of -5% a year, a 5-year average ROIC of 4%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 56% below the current price.
Score: 1.8 / 5
Checks passed
- Strong R&D investment or growth above 20%
- Profitable 5 years in a row
- More cash than debt, or low debt to equity
- Positive free cash flow
- Liabilities below 60% of assets
- Pays a dividend
- Share count down over 3 years (buybacks)
- Dividend 3 years in a row
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.9B | $2.9B | $2.8B | $2.8B | $3.3B | $3.8B | $3.8B | $2.9B | $2.8B | $2.3B | $2.1B |
| Net income | $253M | $241M | $270M | $693M | $569M | $943M | $728M | $228M | $238M | $293M | $234M |
| Free cash flow | $590M | $509M | $542M | $10M | $594M | $1.3B | $829M | $287M | $218M | $249M | $319M |
| EPS (diluted) | $2.25 | $2.07 | $2.20 | $5.55 | $4.50 | $8.08 | $6.49 | $2.04 | $2.13 | $2.64 | $2.12 |
| Net margin | 8.6% | 8.5% | 9.8% | 25.2% | 17.2% | 24.6% | 19.2% | 7.9% | 8.6% | 13.0% | 11.1% |
| ROIC | — | 3.0% | 2.8% | 2.5% | 4.9% | 7.5% | 11.4% | 6.9% | 6.7% | 3.5% | 8.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 15 analysts is $171.40, 11% above the current price; targets range from $122.00 to $200.00; the consensus rating is “Buy”; expected EPS is $5.44 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Revvity’s P/E ratio?
About 68.6, based on the last twelve months of diluted earnings per share (forward P/E about 26.4).
Is Revvity stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 56% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Revvity pay a dividend?
Yes. The dividend yield is about 0.18%, and it has paid dividends for 10 years in our data.
Is Revvity a good stock to buy?
We do not give buy or sell advice. Revvity scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.